Tag: Transgene
Transgene: positive results for TG4050 in head and neck cancer
(AOF) – Transgene and NEC presented the first signs of clinical benefit of their individualized cancer vaccine, TG4050, in head and neck cancers at the annual meeting of the American…
Transgene: 15.7 million in cash at the end of 2023, visibility until the 4th quarter of 2025 – 03/27/2024 at 6:28 p.m.
(AOF) – Transgene displays 15.7 million euros of available cash as of December 31, 2023, compared to 26.8 million euros at the end of 2022, which gives it financial visibility…
Transgene: Lucier Larguier appointed financial director
(AOF) – Transgene announces the appointment of Lucie Larguier to the position of financial director, with immediate effect. This biotech which designs and develops immunotherapies against cancer based on viral…
Transgene: 15.7 million in cash at the end of 2023, visibility until the 4th quarter of 2025
(AOF) – Transgene displays 15.7 million euros of available cash as of December 31, 2023, compared to 26.8 million euros at the end of 2022, which gives it financial visibility…
Transgene: meeting investors
A.S. Published on 03/18/2024 at 6:56 p.m. (Boursier.com) — Transgene will participate, in spring 2024,…
Transgene: James Wentworth appointed chief business officer – 01/22/2024 at 6:01 p.m.
(AOF) – Transgene announces the appointment of James Wentworth to the position of director of business development (chief business officer). This biotechnology company, which designs and develops immunotherapies against cancer…
Transgene: appointment
By Alexandra Saintpierre Published on 01/22/2024 at 5:51 p.m. Photo credit © Transgene (Boursier.com) — Transgene has appointed…
Transgene: James Wentworth appointed chief business officer
(AOF) – Transgene announces the appointment of James Wentworth to the position of director of business development (chief business officer). This biotechnology company, which designs and develops immunotherapies against cancer…
Transgene and NEC Corporation continue clinical development of TG4050
By Olivier Cheilan Published on 01/08/2024 at 5:58 p.m. (Boursier.com) — Transgene and NEC Corporation announced the signing…
Transgene joins forces with NEC for its cancer vaccine
(AOF) – Transgene announces a partnership with NEC Corporation, a Japanese specialist in information technologies, networks and artificial intelligence (AI), relating to the continued clinical evaluation of the individualized neoantigenic…
Transgene Announces Upcoming Investor Meetings – 12/21/2023 at 5:45 p.m.
Strasbourg, December 21, 2023 – 05:45 pm CET TRANSGENE (Paris: TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below.…
Transgene announces its next meetings with investors – 12/21/2023 at 5:45 p.m.
Strasbourg, December 21, 2023, 5:45 p.m. TRANSGENE (Paris: TNG) today announces its participation, in early 2024, in several conferences for investors. Transgene will meet international institutional investors specializing in life…